Welcome to Trovagene Investor Relations
We are a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging our proprietary Precision Cancer Monitoring® (PCM) technology and experience in tumor genomics. Our broad intellectual property and proprietary technology allow us to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting patient response to cancer therapies. We offer our PCM technology at our CLIA/CAP-accredited laboratory and plan to continue to vertically integrate our PCM technology with the development of precision cancer therapeutics. We believe our ctDNA PCM technology and expertise in liquid biopsy testing provides a unique advantage for the development of precision cancer therapeutics.